Delavallée Laure, Assier Eric, Semerano Luca, Bessis Natacha, Boissier Marie-Christophe
Institut National de la Santé et de la Recherche Médicale (INSERM) ERI-18, EA4222, Université Paris 13, Physiopathologie et Biothérapies de la Polyarthrite Rhumatoïde, 74 rue Marcel Cachin, 93017 Bobigny Cedex, France.
Expert Rev Vaccines. 2008 Dec;7(10):1507-17. doi: 10.1586/14760584.7.10.1507.
Most chronic inflammatory diseases have an unknown etiology but all involve cytokine cascade in their development. Several cytokines have been identified as major targets in various autoimmune diseases, resulting in the development of monoclonal antibodies against those cytokines. Even if monoclonal antibodies are indeed efficient, passive immunotherapies present some disadvantages and are expensive. To counter this, several strategies have been developed, including active immunotherapy, based on vaccination principles. The aim of such a strategy is to induce a B-cell response and to obtain autoantibodies able to neutralize the interaction of the self-cytokine to its receptor. Efficient vaccines have to induce a short-term response to avoid permanent inhibition of a given cytokine. This review focuses on the different therapeutic vaccination strategies with cytokines in preclinical studies; the benefit-risk ratio of such a strategy and the present development of clinical trials in some autoimmune diseases are also discussed.
大多数慢性炎症性疾病的病因不明，但在其发展过程中均涉及细胞因子级联反应。几种细胞因子已被确定为各种自身免疫性疾病的主要靶点，从而促使人们开发出针对这些细胞因子的单克隆抗体。即使单克隆抗体确实有效，但被动免疫疗法仍存在一些缺点且成本高昂。为应对这一问题，人们已开发出多种策略，包括基于疫苗接种原理的主动免疫疗法。这种策略的目的是诱导B细胞反应，并获得能够中和自身细胞因子与其受体相互作用的自身抗体。有效的疫苗必须诱导短期反应，以避免对特定细胞因子的永久抑制。本综述重点关注临床前研究中针对细胞因子的不同治疗性疫苗接种策略；还讨论了该策略的利弊比以及目前在某些自身免疫性疾病中的临床试验进展。
